Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, inhibiting the signalling of both IL-4 and IL-13, which are key and central drivers of type 2-mediated inflammation in multiple allergic diseases, especially in AD and asthma [17,18]. Here, IL4 is linked to asthma.